RUNX1 and neoplasm: We have shown the feasibility of using standardized sgRNAs to disrupt the RUNX1-RUNX1T1 in the Kasumi-1 cell line, in both an in vitro setting, to reduce tumor population size and proliferation, and in an in vivo mouse model where RUNX1-RUNX1T1 disruption led to a tumor-volume reduction.